Management of peripheral arterial disease patients: comparing the ACC/AHA and TASC-II guidelines
- PMID: 18664318
- DOI: 10.1185/03007990802274379
Management of peripheral arterial disease patients: comparing the ACC/AHA and TASC-II guidelines
Abstract
Background: Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis associated with a high risk of morbidity and mortality from cardiovascular events. Despite this, PAD is often undiagnosed and, therefore, undertreated.
Objective: The purpose of this review is to highlight and provide clinical insight into the similarities and differences between the available PAD treatment guidelines developed by the American College of Cardiology/American Heart Association (ACC/AHA) and the Trans-Atlantic Inter-Society Consensus II (TASC II) working group.
Methods: Recommendations from the ACC/AHA 2005 Practice Guidelines for the Management of Patients with Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) and TASC II Inter-Society Consensus for the Management of Peripheral Arterial users for personal Disease, initiated in 2004 and published in 2007, were compared. Supplemental information was obtained by searching the PubMed and MEDLINE databases using relevant terms. Unintentional bias may have been introduced into the manuscript by not performing a systematic review of the literature with pre-defined search terms.
Findings and conclusions: While some variation exists in the content of the recommendations, both documents agree on the need for aggressive management of patients with PAD. In spite of these recommendations, there is a general lack of adherence to the current guidelines-a critical concern considering the high morbidity and mortality associated with the disease. However, the results of ongoing clinical trials may serve to increase awareness of the importance of aggressive management of PAD.
Similar articles
-
Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation.Ann Vasc Surg. 2007 Mar;21(2):163-6. doi: 10.1016/j.avsg.2007.01.008. Ann Vasc Surg. 2007. PMID: 17349357
-
ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.J Am Coll Cardiol. 2006 Mar 21;47(6):1239-312. doi: 10.1016/j.jacc.2005.10.009. J Am Coll Cardiol. 2006. PMID: 16545667 No abstract available.
-
ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.Circulation. 2006 Mar 21;113(11):e463-654. doi: 10.1161/CIRCULATIONAHA.106.174526. Circulation. 2006. PMID: 16549646 Review. No abstract available.
-
ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease)--summary of recommendations.J Vasc Interv Radiol. 2006 Sep;17(9):1383-97; quiz 1398. doi: 10.1097/01.RVI.0000240426.53079.46. J Vasc Interv Radiol. 2006. PMID: 16990459 No abstract available.
-
Management of peripheral arterial disease and intermittent claudication.J Am Board Fam Pract. 2001 Nov-Dec;14(6):443-50. J Am Board Fam Pract. 2001. PMID: 11757887 Review.
Cited by
-
Transcatheter arterialization of the deep veins: 1-year outcomes of PROMISE-UK study.Br J Surg. 2024 Jul 2;111(7):znae188. doi: 10.1093/bjs/znae188. Br J Surg. 2024. PMID: 39078986 Free PMC article. No abstract available.
-
Popliteal access for endovascular procedures in femoropopliteal artery occlusive disease.Postepy Kardiol Interwencyjnej. 2023 Sep;19(3):277-283. doi: 10.5114/aic.2023.131482. Epub 2023 Sep 27. Postepy Kardiol Interwencyjnej. 2023. PMID: 37854961 Free PMC article.
-
Polymer Free Amphilimus Drug Eluting Stent for Infrapopliteal Arterial Disease in Patients with Critical Limb Ischemia: A New Device in the Armamentarium.Medicina (Kaunas). 2022 Dec 24;59(1):39. doi: 10.3390/medicina59010039. Medicina (Kaunas). 2022. PMID: 36676663 Free PMC article. Review.
-
One-year outcomes following primary stenting of infrapopliteal steno-occlusive arterial disease using a non-polymer sirolimus-eluting stent: Results from a prospective single-centre cohort study.Front Surg. 2022 Oct 5;9:955211. doi: 10.3389/fsurg.2022.955211. eCollection 2022. Front Surg. 2022. PMID: 36277289 Free PMC article.
-
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia.Mol Ther. 2019 Dec 4;27(12):2158-2165. doi: 10.1016/j.ymthe.2019.10.017. Epub 2019 Oct 31. Mol Ther. 2019. PMID: 31805256 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources